Rallybio

Unimagined Therapies. Undreamed Outcomes.

Despite science’s best efforts, treatments for rare diseases have greatly lagged behind patient needs. It’s time to tackle the undone, the too difficult, and the inaccessible, and change the odds for patients living with rare diseases. Not incrementally — but profoundly.

Breaking news. Breaking conventions.

Our goal is to do more than make headlines. It’s to completely change the narrative for patients with rare diseases.
Read the Latest
Medical professional handling a blood sample in a vial, part of a collection of samples in a lab setting.
Close-up of several blue-tinted biconcave blood cells and one prominent orange-red blood cell against a digital backdrop with DNA strands, hexagonal patterns, and an EKG waveform.

Proof that the odds are improving.

The RLYB116 confirmatory PK/PD study is expected to provide evidence that Rallybio’s C5 inhibitor has the potential to be best-in-class for patients with complement-mediated diseases.
See the Details
Change jobs. Then change the world.
We’re looking for talented people who challenge the status quo and share our passion, focus, and audacious spirit.
Join Us
RB_Home_3
“Our team is composed of innovators with a track record of success in translating scientific breakthroughs into life-changing treatments for people living with rare diseases. We believe our pipeline of assets in complement dysregulation and hematology have best-in-class potential and offer promise and hope to these patients.”
—Steve Uden, M.D., Co-Founder and CEO